The quality of management of patients with gout in real clinical practice
https://doi.org/10.14412/1996-7012-2019-1-80-85
Abstract
Despite the existing guidelines for the management of gout and its potential reversibility, the quality of patient management in general therapy practice remains a serious issue.
Objective: to assess the current state of management of patients with gout in real clinical practice.
Patients and methods. The first stage of the study included an interview with 97 physicians grouped according to their specialties: rheumatologists, general practitioners, and others. The second stage involved an interview with 64 patients with gout who were followed up by physicians of different specialties.
Results and discussion. Physicians most frequently used nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, glucocorticoids (GCs), and allopurinol. Urate-lowering drugs were prescribed mostly by rheumatologists and more rarely by other specialists. The most commonly used drug was allopurinol at a maximum dose 300 mg/day. There was a tendency to a decrease in the number of tophi in the patients who were treated according to the EULAR (European League Against Rheumatism) guidelines. The patients of this group also had lower levels of uric acid (UA) and were more highly adherent to therapy.
The predominant use of NSAIDs in the rare administration of colchicine and GCs, as well as the use of allopurinol to relieve an acute gout attack creates prerequisites for aggravating the disease and decreasing patient compliance. The insufficient dose of allopurinol and no use of prophylactic colchicine for chronic gout contribute to the progression of the disease and the development of its acute attacks. Following the EULAR guidelines makes it possible to achieve the target levels of UA and not only prevent, but also to ensure the regression of gout manifestations, such as tophi.
Conclusion. For radical improvement of the situation, physicians of all specialties should be regularly trained in the management of patients with gout according to the EULAR guidelines.About the Authors
O. V. TeplyakovaRussian Federation
Olga Vyacheslavovna Teplyakova
3, Repin St., Yekaterinburg 620028
A. V. Sarapulova
Russian Federation
3, Repin St., Yekaterinburg 620028
A. A. Popov
Russian Federation
3, Repin St., Yekaterinburg 620028
References
1. Roddy E, Choi H. Epidemiology of Gout. Rheum Dis Clin North Am. 2014 May;40(2): 155-75. doi: 10.1016/j.rdc.2014.01.001. Epub 2014 Feb 19.
2. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 2005 Feb;64(2): 267-72.
3. Folomeeva OM, Galushko EA, Erdes ShF. Prevalence of rheumatic diseases in adult populations of Russian Federation and USA. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2008;46(4):4-13. (In Russ.). doi: 10.14412/1995-4484-2008-529
4. Abeles AM. Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep. 2015 Mar;17(3):13. doi: 10.1007/s11926-015-0495-2.
5. Bardin T, Richette P Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017 Jul 3;15(1):123. doi: 10.1186/s12916-017-0890-9.
6. Mejia-Chew C, Torres RJ, de Miguel E, Puig JG. Resolution of massive tophaceous gout with three urate-lowering drugs. Am J Med. 2013 Nov;126(11):e9-10. doi: 10.1016/j.amjmed.2013.05.009. Epub 2013 Aug 23.
7. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007 Aug;66(8):1056-8. Epub 2007 Jan 12.
8. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978. Epub 2010 Apr 6.
9. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(l):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25.
10. Eliseev MS. New international recommendations for the diagnosis and treatment of gout. Nauchno-prak-ticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):141—6. (In Russ.). doi: 10.14412/1995-4484-2014-141-146
11. Edwards NL Quality of care in patients with gout: why is management suboptimal and what can be done about it? Curr Rheumatol Rep. 2011 Apr;13(2):154-9. doi: 10.1007/s11926-010-0154-6.
12. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053.
13. Федеральный закон «О персональных данных» от 27.07.2006 №152-ФЗ [Federal law "On personal data" dated 27.07.2006 №152-FZ]
14. Bashkova IB, Madyanov IV. Difficulties in the management of patients with gout. Russkii meditsinskiizhurnal. 2015; 23(25):1508-14. (In Russ.).
15. Михневич ЭА. Ошибки и проблемы назначения аллопуринола пациентам с подагрой. Здравоохранение (Минск). 2014;(3):27-31. [Mikhnevich EA. Errors and problems of allopurinol administration in patients with gout. Zdravookhranenie (Minsk). 2014;(3):27-31. (In Russ.)].
16. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, doubleblind, parallel-group trial. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.
Review
For citations:
Teplyakova OV, Sarapulova AV, Popov AA. The quality of management of patients with gout in real clinical practice. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(1):80-85. (In Russ.) https://doi.org/10.14412/1996-7012-2019-1-80-85